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Background: This multicentre study was carried out in Cameroon, Ivory Coast and Senegal to evaluate the
non-inferiority of the new paediatric formulation of artesunate/amodiaquine (AS+AQ)(Camoquin-Plus PaediatricW)
in suspension form versus artemether/lumefantrine (AL)(CoartemW) in the management of African children with
uncomplicated falciparum malaria.
Methods: It was an open randomized trial including children aged between 7 months and 7 years. The endpoints
were Adequate Clinical and Parasitological Response (ACPR) at day 28, the clinical and biological tolerability.
Statistical analyses were done in Intention To Treat (ITT) and in Per protocol (PP).
Results: At the end of the study 481 patients were enrolled in the three countries (249 in the AS+AQ arm and 232
in the AL arm). ACRP in ITT after PCR correction did not show any statistical difference between the two groups
with 97.6% for AS+AQ versus 94.8% for AL. In the PP analysis, the corrected ACRP were respectively 98.7% and
96.9% for the two regimens. The clinical tolerance was good without significant difference. Anaemia was
significantly higher at D7 in the two groups compared to D0.
Conclusion: This study demonstrates the non-inferiority of AS+AQ versus AL, its efficacy and tolerance in the
management of uncomplicated Plasmodium falciparum malaria in African children.
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In spite of all the efforts that have been made over de-
cades, malaria remains a major public health problem in
sub-Saharan Africa. Children are still the main victims of
the disease with a very high mortality rate [1]. Since 2006,
the recommendation by WHO is to use artemisinin-based
combination therapy (ACT) in response to the rise in
resistance to the usual treatment (chloroquine, amodia-
quine or sulphadoxine-pyrimethamine) of uncomplicated
Plasmodium falciparum malaria [2]. Artesunate associated
to amodiaquine (AS+AQ) is one of the formulations of
ACT recommended and widely used in Africa. A large
number of studies showed its efficacy [3]. Unfortunately,
most of the formulations of this combination were not
suitable for children. In response to this, pharmaceutical
firms developed paediatrics formulations more suited to
the treatment of children. Thus, Pfizer laboratories deve-
loped the combination of artesunate and amodiaquine in
suspension form (Camoquin Plus PaediatricW). Few rando-
mized multicentre trials were done with this new formula-
tion. The main focus of this study conducted in 2008 and
2009 in three sites in West Africa (Cameroon, Ivory Coast
and Senegal) was to determine the non-inferiority at day
28 of this new AS+AQ paediatric formulation versus arte-
mether/lumefantrine (CoartemW) in the treatment of
uncomplicated P. falciparum malaria among children aged
between six months and seven years.
Methods
Study site
This study was conducted in three countries, Cameroon
in central Africa, Ivory Coast and Senegal in West Africa.
In Cameroon, the study was performed in the urban
health centre of Melen in Yaoundé, the capital city. In
Ivory Coast, it was done in El Rapha Health Centre of
Abidjan, the capital city, and in Senegal in the health
district of Kaolack located 200 km from Dakar, the
capital city.
Study population
Children above 6 months and under 7 years of age, who
came to the local health centre, with P. falciparum para-
site density between 1,000 and 100,000/μl in a low trans-
mission area (Senegal) and between 2,000 and 200,000/μl
in high transmission areas (Ivory Coast and Cameroon)
[4], with the presence of an axillary temperature higher
than 37.5°C, ability to swallow drugs per os, were
enrolled in the study. Patients presenting severe vomi-
ting, signs of severe malaria [5] or severe malnutrition
(children whose weight-for-height was less than 70% of
the median NCHS/WHO reference value, with a sym-
metrical oedema involving the feet), patients with
allergy to study drugs or who had used any anti-malarial
drug within 28 days prior to enrolment were excluded.Each participant’s guardian gave fully informed written
consent prior to enrolment.
Study procedures
This was a multicentre open, comparative and rando-
mized phase IV trial undertaken in two parallel groups
to test non-inferiority between two associations: AS+AQ
versus artemether/lumefantrine (AL) in children from
six months to seven years. After enrolment, children
were weighed and randomized into blocks of 10 to
receive one of the two drugs.
The formulations of the two associations were the fol-
lowing: AS+AQ in a box with 1 bottle containing AS in
powder dosed a 160mg/80ml to suspend and 1 bottle
containing AQ in syrup dosed at 50mg/5ml. Children
under two years received 10ml of AQ and 20ml of AS
per day and children up to two years received 15ml of
AQ plus 25 ml of AS per day, in a single administration.
AL was presented in fixed tablets containing 20mg of
artemether and 120 mg of lumefantrine. Tablets were
crushed and mixed with water before administration. No
food was given prior the AL administration. It was given
twice a day according to the patient’s bodyweight and
the manufacturer’s instructions. The two drug regimens
covered three days (day 0 to day 2). All the daily doses
were administered at the health post, under the direct
supervision of the investigators. In case of vomiting
within the 30 minutes following the administration,
study doses were administered again to the patient.
Patients who kept vomiting were withdrawn.
Study participants were examined in the study clinic 1,
2, 3, 7, 14, 21, and 28 days after enrolment or at any
time if they did not feel well. Quinine treatment was
given in case of treatment failure which includes : early
treatment failure (development of danger signs or severe
malaria on Day 1, Day 2 or Day 3, in the presence of
parasitaemia, or parasitaemia on Day 2 higher than Day
0 count irrespective of axillary temperature, or parasi-
taemia on Day 3 with axillary temperature ≥3 7.5°C, or
parasitaemia on Day 3 ≥ 25% of count on Day 0) and
late treatment failure (development of danger signs or
severe malaria after Day 3 in the presence of parasit-
aemia, without previously meeting any of the criteria of
early treatment failure or presence of parasitaemia and
axillary temperature ≥ 37.5°C on any day from Day 4 to
Day 28, without previously meeting any of the criteria of
early treatment failure) [4].
Biological follow up
Finger prick to obtain blood for thick and thin smears
were done at Day 1, 2, 3, 7, 14, 21 and Day 28 after
inclusion or at any time if the patients did not feel well.
Blood smears were stained with Giemsa and 200 leuco-
cytes were counted. Assuming a total leukocytes count
*ASAT level higher than 3 times the normal for AS+AQ  
**Severe anemia for AL  
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Withdrawal Consent: 1 
Lost of follow up: 6 
Adverse event*: 1 
Exclusion 
Lost of follow up: 4 
Protocol violation: 2 
Adverse event**: 1  
Population in PP analysis 
at Day 28 : 241
Population in ITT analysis 
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at Day 28 : 232 
Population in PP analysis 
at Day 28 : 225 
Figure 1 Trial profile.
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number of asexual parasites × 8,000/200 [4]. The slide
readers were kept blinded to the treatment allocated.Polymerase chain reaction (PCR)
Four drops of blood were collected on filter paper for
each patient at day 0 and at day of recurrent parasi-
taemia to distinguish recrudescence from new infection.
For this, parasite genotyping by nested PCR was
conducted to compare two polymorphic genetic mar-
kers from Plasmodium falciparum: Merozoite Surface
Protein (msp) genes 1 and 2. The primers and schedules
described by Faye et al [6] were used.Tolerability and safety assessment
All adverse events were closely monitored during each
scheduled visit by interview with patient if possible or
guardian and clinical examination by a physician. All
signs noted were reported in the case report form.Table 1 Demographics characteristics baseline of patients inc
Parameters AS-AQ
Age (median, range) 4 (1 – 7 year
Sex ratio (M/F) 1.2
Weight mean (kg) 15.5 ± 6.4
Axillary temperature mean (°C) 38.8 ± 0.8
Parasite density Geometric mean (P/μl) 11952
± standard deviation.Adverse events were defined as occurring new events or
worsening from baseline after administration of treat-
ment. Haematology and biochemical tests were done at
the enrolment and at Day 7 to evaluate haemoglobin,
creatinine, aspartate amino transferase (ASAT), alanine
amino transferase (ALAT) and bilirubine parameters.
Biological abnormalities were noted.Data statistical analysis
The number of patients to be included in this study was
determined using Epi info software version 6.04d [7], On
the basis of previous studies, the cure rate of AL was
estimated at 95% [8,9]. The maximal difference accep-
table for the AS+AQ to be considered as clinically non-
inferior is 10% (absolute value in percentage) [10,11].
For a statistical power of 80% (β = 20%) a risk α = 5%
and using 95% confidence level sample size for each arm
was 207. In order to prevent premature stops, this num-
ber was increased to 10% given a total of 456 patientsluded
AL p value
s) 5 (1 – 7 years) 0.22
0.9 0.27
16.5 ± 3.7 0.24
38.7 ± 0.8 0.99
13212 0.32
Table 2 Biological parameters evolution between day 0 and day 7
Parameters AS-AQ AL
D0 D7 p D0 D7 p
Mean Hb level (g/dl) 9,5 ± 2 9.3 ± 1.5 0.75 10 ± 2 9.6 ±16 0.63
Anemia 71,9 87,1 <10-3 66,4 78,9 0,002
(Hb < 11g/dl) (%)
Patient with abnormal 8.4 4.4 0,05 7.3 6 0.25
ALAT (<40 UI/L) (%)
Patient with abnormal 30.1 10 <10-3 27.6 12.9 <10-3
ASAT (<40 UI/L) (%)
Mean bilirubine level 11.2 ±8.5 7.3 ±3.6 0.58 11.8 ± 11.4 7.4 ±3.4 0.55
Mean Creatinin level 5.8 ±2.4 5.9 ±2.5 0.99 6 ±2.2 5.8 ± 2.3 0.85
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using Epi info software version 6.04d. All analysis was
done with STATA IC 10TM software.
An intention to treat (ITT) and per protocol (PP) ana-
lysis were done. ITT included all randomized partici-
pants who took at least one full dose and had one post
baseline efficacy assessment without major protocol vio-
lations as wrong dosage, wrong use of non-assigned drug
by mistake, co-infection with other malaria species.
Patients with major violations and patients lost during
the follow-up or withdrawn (due to an adverse event or
to the use of another drug with anti-malarial activity or
withdrawal consent) have been considered as failure.
The per protocol analysis included patients who received
the three doses and who had no major protocol violation
up to the day 28. Those lost to follow up, and the with-
drawals of consent were excluded from the per protocol
analysis.
The primary endpoint was the Adequate Clinical and




Early treatment failure 00
Crude parasitological failure at day 28 05/249 (2%)
PCR adjusted failure rate at day 28 04/249 (1.6%)
PCR adjusted ACPR at day 28 242/249 (97.6%)
Difference, % [95%CI] 2.7 [-0.6 - 6.2%]
PP analysis
Early treatment failure 00
Crude parasitological failure at day 28 05/246 (2%)
PCR adjusted failure rate at day 28 04/246 (1.6%)
PCR adjusted ACPR at day 28 242/246 (98.7%)
Difference, % [95%CI] 1.8 [-0.76 - 4.4]parasitaemia on Day 28 irrespective of axillary temperature
without previously meeting any of the criteria of Early
Treatment Failure or Late Clinical Failure [4]. The cumu-
lative incidence of failure rate was calculated in each study
arm and compared using Kaplan-Meir method. The
secondary endpoints were the comparison of fever and
parasites clearances, gametocytes carriage after treatment
and tolerability of the two regimens.
Data were analysed by estimations of difference in
proportions corresponding to 95% confidence interval.
Comparison between groups was made using chi-square
test or Fisher exact test for qualitative outcome and
student test for quantitative outcome when applicable.
Otherwise, non-parametric tests (Man Withney, Kruskall
Wallis) were used. A p value (two-sided) less than 0.05
was considered statistically significant.
Ethical considerations
The protocol was reviewed and approved by the national









Table 4 Treatment outcome stratified by country
Treatment outcome stratified by country Artesunate/Amodiaquine Artemether/Lumefantrine p value
Senegal (160 patients) 80 80
ITT analysis
Early treatment failure 00 00 –
Crude Parasitological failure at day 28 01/88 (1.1%) 01/72 (1.4%) 1
PCR adjusted failure rate at day 28 01/88 (1.1%) 01/72 (1.4%) 1
PCR adjusted ACPR at day 28 85/88 (96.6%) 67/72 (93.1%) 0.55
% difference 0.3 [-3.3;3.9]
PP analysis
Early treatment failure 00 00 –
Crude Parasitological failure at day 28 01/86 (1.2%) 01/68 (1.5%) 1
PCR adjusted failure rate at day 28 01/86 (1.2%) 01/68 (1.5%) 1
PCR adjusted ACPR at day 28 85/86 (98.8%) 67/68 (98.5%) 0.87
% difference 0.3 [-3.3;3.9]
Ivory Coast (160 patients) 80 80
ITT analysis
Early treatment failure 00 00 –
Crude Parasitological failure at day 28 02/80 (2.5%) 04/80 (2.5%) 0.68
PCR adjusted failure rate at day 28 01/80 (1.3%) 02/80 (2.5%) 1
PCR adjusted ACPR at day 28 79/80 (98.8%) 77/80 (96.3%) 0.36
% difference 2.5 [-0.9;5.9]
PP analysis
Early treatment failure 00 00
Crude Parasitological failure at day 28 02/79 (2.5%) 04/79 (5.1%) 0.68
PCR adjusted failure rate at day 28 01/79 (1.2%) 02/79 (2.5%) 1
PCR adjusted ACPR at day 28 79/79 (100%) 77/79 (97.5%) 0.16
% difference 2.5 [0.9;5.6]
Cameroun (161 patients) 81 80
ITT analysis
Early treatment failure 00 00
Crude Parasitological failure at day 28 02/81 (2.5%) 04/80 (5%) 0.66
PCR adjusted failure rate at day 28 02/81 (2.5%) 04/80 (5%) 0.66
PCR adjusted ACPR at day 28 79/81 (97.5%) 76/80 (95%) 0.40
% difference, 95%CI 2.5% [-3.3;8.4]
PP analysis
Early treatment failure 00 00 –
Crude Parasitological failure at day 28 02/81 (2.5%) 04/80 (5%) 0.66
PCR adjusted failure rate at day 28 02/81 (2.5%) 04/80 (5%) 0.66
PCR adjusted ACPR at day 28 79/81 (97.5%) 76/80 (95%) 0.40
% difference 2.5% [-3.3;8.4]
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Trial profile
In 1,035 patients screened, 481 were included: 249 in AS
+AQ arm and 232 in AL arm (Figure 1). Fifteen patients
were excluded: 10 lost during the follow up, one follo-
wing withdrawal of consent, two for protocol violation
and two patients for high ALAT and ASAT. At the endof the study, 481 patients were included in the ITT ana-
lysis and 466 patients in PP analysis.
Demographics characteristics baseline
The two populations were similar regarding age mean (age
mean, weight mean and sex ratio). Any difference was
noted regarding fever and parasitaemia mean (Table 1).
Figure 2 Kaplan-Meir survival estimates of PCR adjusted ACPR
by treatment arm – ITT analysis.
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Any significant difference was noted between the two
groups regarding the hemoglobin, creatinine and liver
enzymes means (Table 2).Therapeutic efficacy
The ACRP at D28 after PCR correction in ITT analysis
was 97.6% for AS+AQ versus 94.8% for AL (difference
0.027 95% CI [-0.006; 0.062]) (p= 0.11). In PP analysis, it
was 98.7% in AS+AQ arm versus 96.9% in AL arm
(difference 0.18 95% CI [-0.007; 0.044] (p= 0.16). Thus,
the non-inferiority of AS+AQ was shown both in
intention-to-treat and per-protocol analysis. Regarding
treatment failure, after PCR correction, 1.6% (4 patients)
in AS+AQ group and 3.9% (9 patients) in AL group
were considered as recrudescent (Table 3). Any diffe-
rence was obtained in the therapeutic efficacy analysis
done per country (Table 4). The Kaplan Meier analysis
didn’t show any significant difference between the two
group in terms of incidence of failure rate (log rank test:
p= 0.12) (Figure 2).Figure 3 Patients carrying gametocytes from day 0 to day 28 in
the two groups.Fever and parasite clearance
A rapid decrease of fever was noted during the follow-
up in the two groups. At day 0, all patients were feverish.
At day 1, 39% in Al group and 34.7% in AS+AQ group
presented a fever. At day 2, the percentage of patients
with fever decrease to 4.8% and 2.8% respectively in Al
and AS+AQ groups. At day 3, the fever clearance was
total in all the patients. Parasite clearance was faster in
the two groups. At day 2, only 4.8% in AL group and 2%
in AS+AQ presented an asexual parasite stage carriage.
At day 3, the parasite clearance was total. Regarding the
gametocyte carriage, at the inclusion, 13% and 31%, re-
spectively in AS+AQ and AL arms, presented gameto-
cytes. The evolution showed a total clearance starting
from day 1 in AL group, while in AS-AQ group, a per-
sistence of gametocytes until day 3 was noted (Figure 3).
Clinical and biological tolerance
In the two groups, the clinical tolerance was good
(Table 4). Thirty-three patients (13.2%) in AS+AQ group
and fourteen patients in AL group presented at least one
adverse event between day 1 and day 28. Two patients
presented a severe adverse event requiring their exclu-
sion of the study: one in AS+AQ group with an increase
of ASAT with a rate higher than three times the normal
at day 7 and one in AL group presenting a severe
anaemia, with a rate of haemoglobin less than 5g/dl at
day 7. The evolution at day 28 was favourable for these
two patients.
In the two groups, a significant increase of patients
with anaemia (Hb < 11g/dl) [12] between day 0 and day
7 was observed. This was more important in the AS
+AQ group (Table 2). Regarding the hepatic function, an
improvement was noted in the two groups with a signifi-
cant difference for ASAT. Any significant statistical vari-
ation was found for bilirubin and creatinine levels.
Discussion
This multicentre study allowed an evaluation of the effi-
cacy and tolerance of AS+AQ versus AL in three coun-
tries, (Cameroon, Ivory Coast and Senegal) in the
treatment of uncomplicated Plasmodium falciparum
malaria among children between six months and 7 years
of age. The results obtained show that the AS+AQ associ-
ation proved to be very effective with a ACPR rate
adjusted by 97.2% in ITT and 98.3% in PP. Various studies
conducted with artesunate/amodiaquine free combination,
showed comparable efficacies with a non-inferiority to AL
[13] and other formulations of ACT (artesunate/sulpha-
doxine-pyrimethamine, dihydroartemisinine/piperaquine,
artesunate/chlorproguanil-Dapsone) [14-18]. This new
paediatric formulation administered once a day, besides
reducing the number of doses (usually twice a day) con-
firms the efficacy of this association [19]. Similarly, this
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mended by WHO, which allow an efficacy optimization
[20]. However, it should be pointed out that this good
efficacy is highly correlated with a supervised dose admi-
nistration. In fact, several studies demonstrated a lower
efficacy level in case of a non-supervised administration
[21-23]. This drop in compliance when the association is
used in daily practice (non-supervised dose) may in the
long-term result in reduction of efficacy and could lead to
the selection of resistant strains [21].
Fever clearance was fast in both treatment groups,
confirming the previous data [8]. A rapid disappearance
of asexual parasites in the blood has been observed in
both treatment groups with a total body clearance from
day 3. PCR demonstrated a lower recrudescence level in
the AS+AQ group without any significant difference
(p= 0.12). However, gametocyte carriage was longer in
the AS+AQ group with a complete disappearance from
D7. A rapid efficacy of this association on gametocyte
carriage has been demonstrated [24], allowing a reduc-
tion in the P. falciparum transmission.
The clinical tolerance was good with minor adverse
events such as asthenia and vomiting in both treatment
groups. Administering a single daily dose of this new
formulation seems to be well-tolerated and confirms the
previous results [19]. Regarding biological aspects, a sig-
nificant increase in the number of patients presenting an
anaemia has been observed in both groups. This con-
firms the results obtained by Sowunmi et al showing an
increase in anaemia, especially after treatment with the
AS+AQ association [25]. However, the same results
obtained with the AL association seem to suggest an-
other cause different from the amodiaquine effect. Two
serious biological adverse events have been observed;
one in each group at day 7 with a good evolution at day
28. The liver function has been improved significantly in
treatment groups.
Conclusion
This study shows that the new formulation in a suspen-
sion form of the artesunate/amodiaquine association is
as effective as artemether/lumefantrine in the treatment
of uncomplicated P. falciparum malaria in the African
child. The single daily dose may help improve compli-
ance when used in daily practice with non-supervised
administration.
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